- Home
- MGX vs VGAS Comparison
MGX vs VGAS Comparison
Compare MGX & VGAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGX
- VGAS
- Stock Information
- Founded
- MGX 2018
- VGAS 2007
- Country
- MGX United States
- VGAS United States
- Employees
- MGX N/A
- VGAS N/A
- Industry
- MGX
- VGAS Major Chemicals
- Sector
- MGX
- VGAS Industrials
- Exchange
- MGX NYSE
- VGAS Nasdaq
- Market Cap
- MGX 62.1M
- VGAS 73.9M
- IPO Year
- MGX 2024
- VGAS N/A
- Fundamental
- Price
- MGX $2.08
- VGAS $3.49
- Analyst Decision
- MGX Strong Buy
- VGAS
- Analyst Count
- MGX 4
- VGAS 0
- Target Price
- MGX $13.00
- VGAS N/A
- AVG Volume (30 Days)
- MGX 916.2K
- VGAS 11.3K
- Earning Date
- MGX 08-13-2025
- VGAS 08-12-2025
- Dividend Yield
- MGX N/A
- VGAS N/A
- EPS Growth
- MGX N/A
- VGAS N/A
- EPS
- MGX N/A
- VGAS N/A
- Revenue
- MGX $45,263,000.00
- VGAS N/A
- Revenue This Year
- MGX N/A
- VGAS N/A
- Revenue Next Year
- MGX $11.75
- VGAS N/A
- P/E Ratio
- MGX N/A
- VGAS N/A
- Revenue Growth
- MGX N/A
- VGAS N/A
- 52 Week Low
- MGX $1.23
- VGAS $2.76
- 52 Week High
- MGX $5.49
- VGAS $5.46
- Technical
- Relative Strength Index (RSI)
- MGX 62.36
- VGAS 50.63
- Support Level
- MGX $2.04
- VGAS $3.39
- Resistance Level
- MGX $2.47
- VGAS $3.64
- Average True Range (ATR)
- MGX 0.18
- VGAS 0.19
- MACD
- MGX 0.07
- VGAS 0.00
- Stochastic Oscillator
- MGX 61.76
- VGAS 51.43
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
About VGAS Verde Clean Fuels Inc.
Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.